← Patent-cliff monitor small molecule TERLIVAZ TERLIPRESSIN ACETATE
Loss of exclusivity April 2037 latest FDA-listed patent expiry
Company MALLINCKRODT PHARMACEUTICALS IRELAND LTD
Drug detail Brand name TERLIVAZ Active ingredient TERLIPRESSIN ACETATE Strength EQ 0.85MG BASE/VIAL Dosage form POWDER Route INTRAVENOUS Modality Small molecule FDA approval September 2022 Marketing status RX
Listed patents Patent Expires Type 10335452 April 2037 use U-3711
Regulatory exclusivity Code Expires ODE-406 September 2029 NCE September 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.